- The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Sanofi's (NASDAQ:SNY) MenQuadfi, a prophylactic vaccine against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.
- It has also given a thumbs up to Supemtek, its quadrivalent flu vaccine [two A subtypes (H1N1, H3N2) and two B types].
- A final decision from the European Commission usually takes ~60 days.
- Shares up 1% premarket on light volume.